Department of Emergency Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA.
Acad Emerg Med. 2010 Jan;17(1):1-10. doi: 10.1111/j.1553-2712.2009.00625.x.
Beta-blockade is currently recommended in the early management of patients with acute coronary syndromes (ACS). This was a systematic review of the medical literature to determine if early beta-blockade improves the outcome of patients with ACS.
The authors searched the PubMed and EMBASE databases for randomized controlled trials from 1965 through May 2009 using a search strategy derived from the following PICO formulation of our clinical question: Patients included adults (18+ years) with an acute or suspected myocardial infarction (MI) within 24 hours of onset of chest pain. Intervention included intravenous or oral beta-blockers administered within 8 hours of presentation. The comparator included standard medical therapy with or without placebo versus early beta-blocker administration. The outcome was the risk of in-hospital death in the intervention groups versus the comparator groups. The methodologic quality of the studies was assessed. Qualitative methods were used to summarize the study results. In-hospital mortality rates were compared using a forest plot of relative risk (RR; 95% confidence interval [CI]) between beta-blockers and controls. Statistical analysis was done with Review Manager V5.0.
Eighteen articles (total N = 72,249) met the inclusion/exclusion criteria. For in-hospital mortality, RR = 0.95 (95% CI, 0.90-1.01). In the largest of these studies (n = 45,852), a significantly higher rate (p < 0.0001) of cardiogenic shock was observed in the beta-blocker (5.0%) versus control group (3.9%).
This systematic review failed to demonstrate a convincing in-hospital mortality benefit for using beta-blockers early in the course of patients with an acute or suspected MI.
β受体阻滞剂目前被推荐用于急性冠状动脉综合征(ACS)患者的早期治疗。本研究系统回顾了医学文献,以确定早期使用β受体阻滞剂是否能改善 ACS 患者的预后。
作者使用源自我们临床问题的以下 PICO 表述的搜索策略,在 1965 年至 2009 年 5 月期间在 PubMed 和 EMBASE 数据库中搜索随机对照试验:患者包括胸痛发作后 24 小时内发生急性或疑似心肌梗死(MI)的成年人(18 岁以上)。干预措施包括在出现症状后 8 小时内静脉或口服给予β受体阻滞剂。对照组包括标准药物治疗加或不加安慰剂与早期β受体阻滞剂治疗的比较。结局是干预组与对照组的住院期间死亡率。评估了研究的方法学质量。使用森林图汇总研究结果。使用相对风险(RR;95%置信区间[CI])比较β受体阻滞剂和对照组之间的住院死亡率。使用 Review Manager V5.0 进行统计分析。
符合纳入/排除标准的有 18 篇文章(共 N = 72249 人)。对于住院死亡率,RR = 0.95(95% CI,0.90-1.01)。在这些研究中最大的一项(n = 45852)中,β受体阻滞剂组(5.0%)与对照组(3.9%)相比,观察到更高的(p < 0.0001)心源性休克发生率。
本系统综述未能证明在急性或疑似 MI 患者病程早期使用β受体阻滞剂有令人信服的住院死亡率获益。